SCHEMBL6008108

SCHEMBL6008108

CC([NH])C(=O)c1cccc2ccccc12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A1 P22736 1/20 0.57
NR4A2 P43354 1/20 0.57
NR4A3 Q92570 1/20 0.57
PLK1 P53350 1/20 0.55
MMP3 P08254 1/20 0.52
HDAC8 Q9BY41 1/20 0.52
CDC25B P30305 2/20 0.50
PTPN1 P18031 1/20 0.50
POLB P06746 3/20 0.47
KMT2A Q03164 3/20 0.47
KDM4E B2RXH2 2/20 0.47
MEN1 O00255 2/20 0.47
GMNN O75496 2/20 0.47
ALDH1A1 P00352 2/20 0.47
LMNA P02545 2/20 0.47
MAPT P10636 2/20 0.47
HPGD P15428 2/20 0.47
MAPK1 P28482 2/20 0.47
BLM P54132 2/20 0.47
PMP22 Q01453 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32665708 0.84 NR4A1 (0.61) NR4A1NR4A2NR4A3PLK1MMP3
SCHEMBL5716814 0.84 NR4A1 (0.61) NR4A1NR4A2NR4A3PLK1MMP3
SCHEMBL2599103 0.82 NR4A1 (0.59) NR4A1NR4A2NR4A3PLK1MMP3
SCHEMBL2599098 0.82 NR4A1 (0.59) NR4A1NR4A2NR4A3PLK1MMP3
SCHEMBL25057402 0.81 NR4A1 (0.57) NR4A1NR4A2NR4A3PLK1MMP3
SCHEMBL10358074 0.81 NR4A1 (0.57) NR4A1NR4A2NR4A3PLK1MMP3
SCHEMBL4099062 0.81 NR4A1 (0.57) NR4A1NR4A2NR4A3PLK1MMP3
SCHEMBL5125965 0.81 NR4A1 (0.57) NR4A1NR4A2NR4A3PLK1MMP3
SCHEMBL6008119 0.81 NR4A1 (0.57) NR4A1NR4A2NR4A3PLK1MMP3
SCHEMBL4828437 0.79 NR4A1 (0.55) NR4A1NR4A2NR4A3PLK1MMP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1207161-B1 NOVEL ISOINDOLE DERIVATIVES BANYU PHARMA CO LTD (JP) 2006-01-18 EP disclosed
US-6777410-B2 SUCH AS 9-(2-METHOXYPHENYL)-3-(1-METHYLETHYL)-(1,3)OXAZOLO-(2,3)ISOINDOLE-2,5(3H,9H)-DIONE; DIABETES AND COMPLICATIONS; OBESITY BANYU PHARMACEUTICAL CO., LTD. (JP) 2004-08-17 US disclosed
US-20040053923-A1 Novel isoindole derivatives BANYU PHARMACEUTICAL CO., LTD. 2004-03-18 US disclosed
US-6608098-B1 Diabetes or obesity, 2-(4-(3-isopropyl-2,5-dioxo-2,3-dihydro-1H-pyrrolo(2,1-a) isoindol-9(5H)-yl)phenoxy)-N-propylacetamide BANYU PHARMACEUTICAL CO., LTD. (JP) 2003-08-19 US disclosed
EP-1207161-A1 NOVEL ISOINDOLE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2002-05-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053923-A1 Novel isoindole derivatives GPR119, SLC5A2, SLC5A1 NR4A1 785/4885NR4A2 796/4885NR4A3 782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.